Article thumbnail

Assessment of Anti-Cytogenotoxic Effects of Quercetin in Animals Treated with Topotecan

By Saleh A. Bakheet

Abstract

The present investigation was directed to study the possible chemoprotective activity of orally administered quercetin against topotecan-induced cyto- and genotoxicity towards mouse somatic cells in vivo. DNA strand breaks, micronuclei formation, and mitotic activity were undertaken in the current study as markers of cyto- and genotoxicity. Oxidative stress markers such as intracellular reactive oxygen species generation, lipid peroxidation, and reduced and oxidized glutathione were assessed in bone marrow as a possible mechanism underlying this amelioration. Quercetin was neither cytotoxic nor genotoxic in mice at doses tested. Pretreatment of mice with quercetin significantly reduced topotecan-induced genotoxicity and cytotoxicity in bone marrow cells, and these effects were dose dependent. Moreover, prior administration of quercetin ahead of topotecan challenge ameliorated oxidative stress markers. In conclusion, quercetin has a protective role in the abatement of topotecan-induced cyto- and genotoxicity in the bone marrow cells of mice that resides, at least in part, on its antioxidant effects. Based on the data presented, strategies can be developed to decrease the topotecan-induced bone marrow suppression and secondary malignancy in cancer patients and medical personnel exposing to topotecan

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3163490
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Abatement by naringin of lomefloxacin-induced genomic instability
  2. (2011). Al-Rasheed et al., “Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells,”
  3. Antimutagenic activity of flavonoids from Chrysanthemum morifolium,”
  4. (2005). Antimutagenic and antioxidant/prooxidant activity of quercetin,’’
  5. (1979). Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction,”
  6. (2001). C h o i ,J .Y .K i m ,J .Y .L e ee ta l . ,“ I n d u c t i o no fc e l l cycle arrest and apoptosis in human breast cancer cells by quercetin,” InternationalJournalofOncology,v ol.19,no .4,p p .
  7. (2006). Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and IImechanisms of action, pharmacokinetics and toxicity profile,”
  8. (2004). Camptothecins in clinical development,”
  9. (2008). Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer,”
  10. (1998). Continuing Survey of Food Intakes by Individuals (CSFII) and Diet and Health Knowledge Survey (DHKS) (On CD-ROM),
  11. (2002). Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins,”
  12. (2007). Deletion of theshortarmofchromosome1(del1p)isastrongpredictorof poor outcome in myeloma patients undergoing an autotransplant,”
  13. (1985). Determination of glutathione and glutathione disulfide in biological samples,” in Methods Enzymology,
  14. (1998). Differential effects of camptothecin derivatives on topoisomerase
  15. (1996). Discovery to clinic,”
  16. (2005). Efficacy of topotecan treatment on antioxidant enzymes and TBA-RS levels in submandibular glands of rabbits: an experimental study,”
  17. (2003). Flavonoid effect on normal and leukemic cells,”
  18. (2003). Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo,”
  19. (1990). Harrington-Brock et al.,
  20. (2005). Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis,”
  21. (1992). In hibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cisdiamminedichloroplatinum (II),”
  22. (1990). Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and culturedcells,”BritishJournalofCancer,vol.62,no.6,pp.942– 946,
  23. (1951). L o w r y ,N .J .R o s e b r o u g h ,A .L .F a r r ,a n dR .J .R a n d a l l , “Protein measurement with Folin phenol reagent,”
  24. (2009). Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan,
  25. (2006). o r t i b r ´ a n
  26. (2008). Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of
  27. (2010). Proanthocyanidins produce significant attenuation of doxorubicininduced mutagenicity via suppression of oxidative stress,’’ Oxidative Medicine and Cellular Longevity,v o l .3 ,n o .6 ,p p .
  28. (2007). Prolonged quercetin administration diminishes the etoposide-induced DNA damage in bone marrow cells of rats,”
  29. (2001). Quercetin prevents glutathione depletion inducedbydehydroascorbic acidinrabbit redblood cells,”
  30. (2005). Reversal of multidrug resistance of HL-60 adriamycin resistant leukemia cell line by quercetin and its mechanisms,” Zhonghua Zhong Liu Za Zhi,
  31. (2007). Safety of topotecan in the treatment of recurrent small cell lung cancer and ovarian cancer,”
  32. (2000). Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing,” Environmental and Molecular Mutagenesis,
  33. (2008). The changes of antioxidant defense system caused by quercetin administration do not lead to DNA damage and apoptosis in the spleen and bone marrow cells of rats,”
  34. (2005). The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells,”
  35. The effects of topotecanonlipidperoxidationandantioxidantenzymelevels in rabbit liver tissue,”
  36. (2007). The genotoxic and cytotoxic effects of nicotine
  37. (2010). The impact of quercetin on cisplatin-induced clastogenesis and apoptosis in murine marrow cells,”
  38. (1959). Tissue sulfhydryl groups,”
  39. (2006). Topoisomerase I inhibitors: camptothecins and beyond,”